Dr Ruth Pidsley
Dr Ruth Pidsley is an NHMRC Investigator Fellow, Group Leader of the DNA Methylation Biomarkers group at the Garvan Institute of Medical Research and Conjoint Lecturer at St Vincent's Clinical School, UNSW Sydney. She graduated with a degree in Human Sciences from Oxford University, before studying for an MSc/PhD at King's College London, investigating epigenetics in the human brain and neuropsychiatric disorders. In 2013 she transitioned to cancer research, joining Professor Susan Clark’s Epigenetics Research Lab at Garvan, and established her own research group in 2018.
The research in Ruth's group focuses primarily on the role of epigenetics in the prostate tumour microenvironment. Their goal is to use this epigenetic information to improve cancer diagnosis and prognosis, so that patients can receive the correct treatment.
Since starting her scientific career in 2007, Ruth has published more than 35 papers, she has co-supervised the research projects of MSc and undergraduate students, as well as lecturing on two MSc courses. She has been awarded competitive funding for research projects from CINSW, CCNSW and NHMRC. She has contributed to further improving the research environment through serving on Garvan’s Postdoctoral Development and Engagement Committees and the NSW Australian Society for Medical Research (ASMR) Committee. Ruth also engages with patient consumers to guide her research and shares her research outcomes with the general public through public events at Garvan.
Awards
- 2022NHMRC Investigator Fellowship
- 2015Cancer Institute New South Wales Early Career Fellowship
- 2013Gottesman-Shields Award for best PhD at the MRC SGDP Department - King’s College London - UK
- 2012Tadion Rideal Prize for best PhD across the biomedical sciences at King’s College London - UK
- 2008MRC Studentship for MSc/PhD course at the MRC SGDP Department - King’s College London - UK
Selected publications
See all publications- 2024BMC Genomics10.1186/s12864-024-10027-5
Characterisation and reproducibility of the HumanMethylationEPIC v2.0 BeadChip for DNA methylation profiling.
- 2024The Journal of Pathology10.1002/path.6250
Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma.
- 2024Nature Structural & Molecular Biology10.1038/s41594-023-01181-7
The potential of epigenetic therapy to target the 3D epigenome in endocrine-resistant breast cancer.
- 2023Nature Cancer10.1038/s43018-023-00614-y
A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer.
- 2022Clinical and Translational Medicine10.1002/ctm2.1030
Comprehensive methylome sequencing reveals prognostic epigenetic biomarkers for prostate cancer mortality.